Pasithea Therapeutics (KTTA) Directors and Executive Officers

Officers & Directors

Daniel Schneiderman
Chief Financial Officer - (Principal Financial and Accounting Officer)

Alfred Novak
Director

Dr. Tiago Reis Marques
Chief Executive Officer and Director - (Principal Executive Officer)

Simon Dumesnil
Director

Prof. Lawrence Steinman
Director

Dr. Emer Leahy
Director

Marcum LLP
We have served as the Company’s auditor - since ,

Pasithea Therapeutics Corp currently has 5 employees.

News about Pasithea Therapeutics Corp Key Personnel

Pasithea Therapeutics Appoints Dr. Rebecca Brown to Scientific Advisory Board and Completes Successful Tender Offer Acquisition, Building Investor Confidence and Enhancing Growth Potential,

Pasithea Therapeutics, a leading biotech company, has recently appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, an expert in Neurofibromatosis and Director at Mount Sinai, will be instrumental in providing her expertise to aid in the development of PAS-004. This appointment highlights Pasithea Therapeutics commitment to advancing medical research and finding innovative treatments for patients.
In addition to this exciting appointment, Pasithea Therapeutics also reported a cumulative net loss of $-15 million during the 12 months ending in the second quarter of 2024, resulting in a negative return on investment (ROI) of -49.28%. This financial performance indicates challenges ...

Pasithea Therapeutics Reports Positive Pre-IND Meeting Outcome but Faces Financial Struggles with a Negative ROI

Pasithea Therapeutics Faces Financial Challenges Amid Positive Clinical Development Outcome
Pasithea Therapeutics Corp, a healthcare company specializing in MEK inhibitor development, recently announced the outcome of its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical development of its PAS-004 drug. Despite positive progress in drug development, the company s financial performance has been concerning, as it recorded a cumulative net loss of $16 million during the 12 months ending in the third quarter of 2023. This resulted in a negative return on investment (ROI) of -43.82%.
Within the healthcare sector, Pasithea Therapeutics falls ...